camostat has been researched along with 2019 Novel Coronavirus Disease in 35 studies
camostat : A benzoate ester resulting from the formal condensation of the carboxy group of 4-guanidinobenzoic acid with the hydroxy group of 2-(dimethylamino)-2-oxoethyl (4-hydroxyphenyl)acetate. It is a potent inhibitor of the human transmembrane protease serine 2 (TMPRSS2) and its mesylate salt is currently under investigation for its effectiveness in COVID-19 patients.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Camostat mesilate is a drug that is being repurposed for new applications such as that against COVID-19 and prostate cancer." | 1.62 | Determination of camostat and its metabolites in human plasma - Preservation of samples and quantification by a validated UHPLC-MS/MS method. ( Gunst, JD; Hasselstrøm, JB; Kjolby, M; Søgaard, OS; Sørensen, LK, 2021) |
| "Pretreatment with camostat (0." | 1.56 | Protease Inhibitors: Candidate Drugs to Inhibit Severe Acute Respiratory Syndrome Coronavirus 2 Replication. ( Deng, X; Kikuchi, A; Nagatomi, R; Nishimura, H; Yamaya, M, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 35 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gordon, DE | 1 |
| Jang, GM | 1 |
| Bouhaddou, M | 1 |
| Xu, J | 1 |
| Obernier, K | 1 |
| White, KM | 1 |
| O'Meara, MJ | 1 |
| Rezelj, VV | 1 |
| Guo, JZ | 1 |
| Swaney, DL | 1 |
| Tummino, TA | 1 |
| Hüttenhain, R | 1 |
| Kaake, RM | 1 |
| Richards, AL | 1 |
| Tutuncuoglu, B | 1 |
| Foussard, H | 1 |
| Batra, J | 1 |
| Haas, K | 1 |
| Modak, M | 1 |
| Kim, M | 1 |
| Haas, P | 1 |
| Polacco, BJ | 1 |
| Braberg, H | 1 |
| Fabius, JM | 1 |
| Eckhardt, M | 1 |
| Soucheray, M | 1 |
| Bennett, MJ | 1 |
| Cakir, M | 1 |
| McGregor, MJ | 1 |
| Li, Q | 1 |
| Meyer, B | 1 |
| Roesch, F | 1 |
| Vallet, T | 1 |
| Mac Kain, A | 1 |
| Miorin, L | 1 |
| Moreno, E | 1 |
| Naing, ZZC | 1 |
| Zhou, Y | 2 |
| Peng, S | 1 |
| Shi, Y | 1 |
| Zhang, Z | 1 |
| Shen, W | 1 |
| Kirby, IT | 1 |
| Melnyk, JE | 1 |
| Chorba, JS | 1 |
| Lou, K | 1 |
| Dai, SA | 1 |
| Barrio-Hernandez, I | 1 |
| Memon, D | 1 |
| Hernandez-Armenta, C | 1 |
| Lyu, J | 1 |
| Mathy, CJP | 1 |
| Perica, T | 1 |
| Pilla, KB | 1 |
| Ganesan, SJ | 1 |
| Saltzberg, DJ | 1 |
| Rakesh, R | 1 |
| Liu, X | 1 |
| Rosenthal, SB | 1 |
| Calviello, L | 1 |
| Venkataramanan, S | 1 |
| Liboy-Lugo, J | 1 |
| Lin, Y | 1 |
| Huang, XP | 1 |
| Liu, Y | 1 |
| Wankowicz, SA | 1 |
| Bohn, M | 1 |
| Safari, M | 1 |
| Ugur, FS | 1 |
| Koh, C | 1 |
| Savar, NS | 1 |
| Tran, QD | 1 |
| Shengjuler, D | 1 |
| Fletcher, SJ | 1 |
| O'Neal, MC | 1 |
| Cai, Y | 1 |
| Chang, JCJ | 1 |
| Broadhurst, DJ | 1 |
| Klippsten, S | 1 |
| Sharp, PP | 1 |
| Wenzell, NA | 1 |
| Kuzuoglu-Ozturk, D | 1 |
| Wang, HY | 1 |
| Trenker, R | 1 |
| Young, JM | 1 |
| Cavero, DA | 1 |
| Hiatt, J | 1 |
| Roth, TL | 1 |
| Rathore, U | 1 |
| Subramanian, A | 1 |
| Noack, J | 1 |
| Hubert, M | 1 |
| Stroud, RM | 1 |
| Frankel, AD | 1 |
| Rosenberg, OS | 1 |
| Verba, KA | 1 |
| Agard, DA | 1 |
| Ott, M | 1 |
| Emerman, M | 1 |
| Jura, N | 1 |
| von Zastrow, M | 1 |
| Verdin, E | 1 |
| Ashworth, A | 1 |
| Schwartz, O | 1 |
| d'Enfert, C | 1 |
| Mukherjee, S | 1 |
| Jacobson, M | 1 |
| Malik, HS | 1 |
| Fujimori, DG | 1 |
| Ideker, T | 1 |
| Craik, CS | 2 |
| Floor, SN | 1 |
| Fraser, JS | 1 |
| Gross, JD | 1 |
| Sali, A | 1 |
| Roth, BL | 1 |
| Ruggero, D | 1 |
| Taunton, J | 1 |
| Kortemme, T | 1 |
| Beltrao, P | 1 |
| Vignuzzi, M | 1 |
| García-Sastre, A | 1 |
| Shokat, KM | 1 |
| Shoichet, BK | 1 |
| Krogan, NJ | 1 |
| Jeon, S | 1 |
| Ko, M | 1 |
| Lee, J | 1 |
| Choi, I | 1 |
| Byun, SY | 1 |
| Park, S | 1 |
| Shum, D | 1 |
| Kim, S | 1 |
| Choudhry, N | 1 |
| Zhao, X | 1 |
| Xu, D | 1 |
| Zanin, M | 1 |
| Chen, W | 1 |
| Yang, Z | 1 |
| Chen, J | 1 |
| Pillaiyar, T | 1 |
| Wendt, LL | 1 |
| Manickam, M | 1 |
| Easwaran, M | 1 |
| Shapira, T | 1 |
| Monreal, IA | 1 |
| Dion, SP | 1 |
| Buchholz, DW | 1 |
| Imbiakha, B | 1 |
| Olmstead, AD | 1 |
| Jager, M | 1 |
| Désilets, A | 1 |
| Gao, G | 1 |
| Martins, M | 1 |
| Vandal, T | 1 |
| Thompson, CAH | 1 |
| Chin, A | 1 |
| Rees, WD | 1 |
| Steiner, T | 1 |
| Nabi, IR | 1 |
| Marsault, E | 1 |
| Sahler, J | 1 |
| Diel, DG | 1 |
| Van de Walle, GR | 1 |
| August, A | 1 |
| Whittaker, GR | 1 |
| Boudreault, PL | 1 |
| Leduc, R | 1 |
| Aguilar, HC | 1 |
| Jean, F | 1 |
| Mahoney, M | 1 |
| Damalanka, VC | 1 |
| Tartell, MA | 1 |
| Chung, DH | 1 |
| Lourenço, AL | 1 |
| Pwee, D | 1 |
| Mayer Bridwell, AE | 1 |
| Hoffmann, M | 3 |
| Voss, J | 1 |
| Karmakar, P | 1 |
| Azouz, NP | 1 |
| Klingler, AM | 1 |
| Rothlauf, PW | 1 |
| Thompson, CE | 1 |
| Lee, M | 1 |
| Klampfer, L | 1 |
| Stallings, CL | 1 |
| Rothenberg, ME | 1 |
| Pöhlmann, S | 3 |
| Whelan, SPJ | 1 |
| O'Donoghue, AJ | 1 |
| Janetka, JW | 1 |
| Zhao, H | 1 |
| Lu, L | 1 |
| Peng, Z | 1 |
| Chen, LL | 1 |
| Meng, X | 1 |
| Zhang, C | 1 |
| Ip, JD | 1 |
| Chan, WM | 1 |
| Chu, AW | 1 |
| Chan, KH | 1 |
| Jin, DY | 1 |
| Chen, H | 1 |
| Yuen, KY | 1 |
| To, KK | 1 |
| Guo, W | 1 |
| Porter, LM | 1 |
| Crozier, TW | 1 |
| Coates, M | 1 |
| Jha, A | 1 |
| McKie, M | 1 |
| Nathan, JA | 1 |
| Lehner, PJ | 1 |
| Greenwood, EJ | 1 |
| McCaughan, F | 1 |
| Ledford, H | 1 |
| Wu, T | 1 |
| Rabi, SA | 1 |
| Michaud, WA | 1 |
| Becerra, D | 1 |
| Gilpin, SE | 1 |
| Mino-Kenudson, M | 1 |
| Ott, HC | 1 |
| C, AM | 1 |
| Wessler, S | 1 |
| Ponnuraj, K | 1 |
| Jilg, N | 1 |
| Chew, KW | 1 |
| Giganti, MJ | 1 |
| Daar, ES | 1 |
| Wohl, DA | 1 |
| Javan, AC | 1 |
| Kantor, A | 1 |
| Moser, C | 1 |
| Coombs, RW | 1 |
| Neytman, G | 1 |
| Hoover, K | 1 |
| Jana, A | 1 |
| Hart, PA | 1 |
| Greninger, AL | 1 |
| Szurgot, B | 1 |
| Eron, JJ | 1 |
| Currier, JS | 1 |
| Hughes, MD | 1 |
| Smith, DM | 1 |
| Li, JZ | 1 |
| Kondo, A | 1 |
| Fujimoto, KJ | 1 |
| Yanai, T | 1 |
| Kleine-Weber, H | 1 |
| Schroeder, S | 1 |
| Krüger, N | 2 |
| Herrler, T | 1 |
| Erichsen, S | 1 |
| Schiergens, TS | 1 |
| Herrler, G | 1 |
| Wu, NH | 1 |
| Nitsche, A | 1 |
| Müller, MA | 1 |
| Drosten, C | 1 |
| Henrickson, SE | 1 |
| Stopsack, KH | 1 |
| Mucci, LA | 1 |
| Antonarakis, ES | 1 |
| Nelson, PS | 1 |
| Kantoff, PW | 1 |
| Uno, Y | 1 |
| Zhou, H | 1 |
| Fang, Y | 1 |
| Xu, T | 1 |
| Ni, WJ | 1 |
| Shen, AZ | 1 |
| Meng, XM | 1 |
| Rahman, N | 1 |
| Basharat, Z | 1 |
| Yousuf, M | 1 |
| Castaldo, G | 1 |
| Rastrelli, L | 1 |
| Khan, H | 1 |
| Yamaya, M | 1 |
| Nishimura, H | 1 |
| Deng, X | 1 |
| Kikuchi, A | 1 |
| Nagatomi, R | 1 |
| Nitulescu, GM | 1 |
| Paunescu, H | 1 |
| Moschos, SA | 1 |
| Petrakis, D | 1 |
| Nitulescu, G | 1 |
| Ion, GND | 1 |
| Spandidos, DA | 1 |
| Nikolouzakis, TK | 1 |
| Drakoulis, N | 1 |
| Tsatsakis, A | 1 |
| Yamamoto, M | 1 |
| Kiso, M | 1 |
| Sakai-Tagawa, Y | 1 |
| Iwatsuki-Horimoto, K | 1 |
| Imai, M | 1 |
| Takeda, M | 1 |
| Kinoshita, N | 1 |
| Ohmagari, N | 1 |
| Gohda, J | 1 |
| Semba, K | 1 |
| Matsuda, Z | 1 |
| Kawaguchi, Y | 1 |
| Kawaoka, Y | 1 |
| Inoue, JI | 1 |
| Giovane, RA | 1 |
| Rezai, S | 1 |
| Cleland, E | 1 |
| Henderson, CE | 1 |
| Mollica, V | 1 |
| Rizzo, A | 1 |
| Massari, F | 1 |
| Kishk, SM | 1 |
| Kishk, RM | 1 |
| Yassen, ASA | 1 |
| Nafie, MS | 1 |
| Nemr, NA | 1 |
| ElMasry, G | 1 |
| Al-Rejaie, S | 1 |
| Simons, C | 1 |
| Nabavi, SF | 1 |
| Habtemariam, S | 1 |
| Berindan-Neagoe, I | 1 |
| Cismaru, CA | 1 |
| Schaafsma, D | 1 |
| Ghavami, S | 1 |
| Banach, M | 1 |
| Aghaabdollahian, S | 1 |
| Nabavi, SM | 1 |
| Ramakrishnan, J | 1 |
| Kandasamy, S | 1 |
| Iruthayaraj, A | 1 |
| Magudeeswaran, S | 1 |
| Chinnasamy, K | 1 |
| Poomani, K | 1 |
| Ellinger, B | 1 |
| Bojkova, D | 1 |
| Zaliani, A | 1 |
| Cinatl, J | 1 |
| Claussen, C | 1 |
| Westhaus, S | 1 |
| Keminer, O | 1 |
| Reinshagen, J | 1 |
| Kuzikov, M | 1 |
| Wolf, M | 1 |
| Geisslinger, G | 1 |
| Gribbon, P | 1 |
| Ciesek, S | 1 |
| Sakr, Y | 1 |
| Bensasi, H | 1 |
| Taha, A | 1 |
| Bauer, M | 1 |
| Ismail, K | 1 |
| Sun, G | 1 |
| Sui, Y | 1 |
| Ya, J | 1 |
| Yuan, C | 1 |
| Jiang, L | 1 |
| Huang, M | 1 |
| Huang, X | 1 |
| Pearce, R | 1 |
| Omenn, GS | 1 |
| Zhang, Y | 1 |
| Sørensen, LK | 1 |
| Hasselstrøm, JB | 1 |
| Gunst, JD | 1 |
| Søgaard, OS | 1 |
| Kjolby, M | 1 |
| Hofmann-Winkler, H | 1 |
| Kempf, A | 1 |
| Nehlmeier, I | 1 |
| Graichen, L | 1 |
| Arora, P | 1 |
| Sidarovich, A | 1 |
| Moldenhauer, AS | 1 |
| Winkler, MS | 1 |
| Schulz, S | 1 |
| Jäck, HM | 1 |
| Stankov, MV | 1 |
| Behrens, GMN | 1 |
| Halford, S | 1 |
| Wan, S | 1 |
| Dragoni, I | 1 |
| Silvester, J | 1 |
| Nazarov, B | 1 |
| Anthony, D | 1 |
| Anthony, S | 1 |
| Ladds, E | 1 |
| Norrie, J | 1 |
| Dhaliwal, K | 1 |
| Yadav, PK | 1 |
| Jaiswal, A | 1 |
| Singh, RK | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Studying the Efficiency of the Natural Preparation Rutan in Children in the Treatment of COVID-19, Acute Respiratory Viral Infections, and Developing Treatment Protocols[NCT05862883] | Phase 2 | 301 participants (Actual) | Interventional | 2021-06-01 | Completed | ||
| COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19)[NCT04510194] | Phase 3 | 1,323 participants (Actual) | Interventional | 2021-01-01 | Active, not recruiting | ||
| Evaluation of Silver Nanoparticles as an Oropharyngeal Product (Mouthwash) and Nasal Hygiene, by Health Personnel Working at the Tijuana General Hospital Exposed to Patients Diagnosed With Atypical Pneumonia Caused by SARS-CoV-2[NCT04894409] | 231 participants (Actual) | Interventional | 2020-04-24 | Completed | |||
| A Novel Nasal Treatment for COVID-19[NCT05799521] | Phase 2 | 40 participants (Anticipated) | Interventional | 2023-06-27 | Recruiting | ||
| CORONA: A Phase 1/2 Study Using DeltaRex-G Gene Therapy for Symptomatic COVID-19[NCT04378244] | Phase 1/Phase 2 | 0 participants (Actual) | Interventional | 2022-12-12 | Withdrawn (stopped due to Lack of Funding) | ||
| The Use of Brazilian Green Propolis Extract (EPP-AF) in Patients Affected by COVID-19: a Randomized, Open and Pilot Clinical Study.[NCT04480593] | Phase 2/Phase 3 | 120 participants (Actual) | Interventional | 2020-06-02 | Completed | ||
| Apelin; ACE2 and Biomarkers of Alveolar-capillary Permeability in SARS-cov-2 (COVID-19).[NCT04632732] | 140 participants (Actual) | Observational [Patient Registry] | 2020-10-26 | Completed | |||
| Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals (ELEVATE Trial)[NCT04340349] | Early Phase 1 | 214 participants (Anticipated) | Interventional | 2021-02-01 | Enrolling by invitation | ||
| Randomized, Double-blind, Placebo-controlled, Multicenter, Multi-arm, Phase II Trial of Novel Agents for the Treatment of Mild to Moderate COVID-19 Positive Outpatients[NCT04530617] | Phase 2 | 246 participants (Actual) | Interventional | 2020-10-05 | Terminated (stopped due to Results from the interim analysis) | ||
| Pilot Study on Peripheral Vascular Function in Covid-19 Patient[NCT04625036] | 22 participants (Actual) | Observational [Patient Registry] | 2020-05-30 | Completed | |||
| The Randomized Elimination or Prolongation of Angiotensin Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Coronavirus Disease 2019[NCT04338009] | 152 participants (Actual) | Interventional | 2020-03-31 | Completed | |||
| Pilot Phase II Randomized, Placebo-Controlled Clinical Trial for the Prevention and Progression of SARS-CoV-2 Infection of Subjects and Patients Using a Supplement Treatment With Carnipure Tartrate ( LCLT)[NCT05446961] | Phase 2 | 224 participants (Actual) | Interventional | 2021-03-01 | Completed | ||
| The Use of the Standardized Brazilian Green Propolis Extract (EPP-AF) as an Adjunct Treatment for Hospitalized COVID-19 Patients: A Randomized, Double-blind, Placebo-controlled Trial[NCT04800224] | Phase 2/Phase 3 | 200 participants (Actual) | Interventional | 2021-04-12 | Completed | ||
| Treatment Effect of Nafamostat Mesylate in Patients With COVID-19 Pneumonia: Open Labelled Randomized Controlled Clinical Trial[NCT04418128] | Phase 2/Phase 3 | 84 participants (Anticipated) | Interventional | 2020-06-10 | Not yet recruiting | ||
| A Phase I/III Randomized, Double Blind Study to Evaluate the Safety, Efficacy and Neutralizing Activity of AZD5156/AZD3152 for Pre Exposure Prophylaxis of COVID 19 in Participants With Conditions Causing Immune Impairment. Sub-study: Phase II Open Label S[NCT05648110] | Phase 2/Phase 3 | 4,038 participants (Actual) | Interventional | 2022-12-16 | Active, not recruiting | ||
| Dynamics of Hemostatic Parameters in COVID-19 and Comparison of Intervention Strategies Through Adaptive Clinical Trial[NCT04466670] | Phase 2 | 379 participants (Anticipated) | Interventional | 2020-07-11 | Recruiting | ||
| Impact of the Genetic Polymorphism on the Severity of COVID-19 Infection in Egyptian Patients[NCT05157217] | 98 participants (Anticipated) | Observational | 2021-12-15 | Recruiting | |||
| Phase II Study to Evaluate Immunogenicity and Safety in Subjects With Evidence of Prior Immunity to SARS-CoV-2 of a Single Intramuscular or Intranasal Dose of the Live Recombinant Newcastle Disease Virus Based AVX/COVID-12 Vaccine[NCT05205746] | Phase 2 | 158 participants (Actual) | Interventional | 2021-11-23 | Completed | ||
| Phase II/III Parallel, Double-blind, Non-inferiority Study With Active Control, to Evaluate the Immunogenicity and Safety of a Booster Immunization Scheme With a Single Intramuscular Dose of the Recombinant Vaccine Against SARS-CoV-2[NCT05710783] | Phase 2/Phase 3 | 4,065 participants (Actual) | Interventional | 2022-11-09 | Completed | ||
| A Clinical Trial of Nebulized Surfactant for the Treatment of Moderate to Severe COVID-19[NCT04362059] | 20 participants (Actual) | Interventional | 2020-06-18 | Completed | |||
| RAndomized Clinical Trial in COvid19 Patients to Assess the Efficacy of the Transmembrane Protease Serine 2 (TMPRSS2) Inhibitor NAfamostat (RACONA Study)[NCT04352400] | Phase 2/Phase 3 | 256 participants (Anticipated) | Interventional | 2021-06-04 | Recruiting | ||
| Detection Rate of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) in Male Genitourinary System and Its Impact on Male Reproductive Health: an Observational Clinical Study.[NCT04388631] | 200 participants (Anticipated) | Observational [Patient Registry] | 2020-05-10 | Recruiting | |||
| Efficacy of Gabapentin for Post-Covid-19 Olfactory Dysfunction[NCT05184192] | Phase 2 | 50 participants (Anticipated) | Interventional | 2022-01-10 | Enrolling by invitation | ||
| A Randomised Phase II Trial in Early COVID-19, Assessing Use of Camostat by Blocking SARS-CoV-2 Spike Protein-initiated Membrane Fusion.[NCT04455815] | Phase 2 | 34 participants (Actual) | Interventional | 2020-09-23 | Terminated (stopped due to Sponsor decision) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT04510194)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Arm - Metformin Only Group | 0 |
| Treatment Arm - Placebo Group | 0 |
| Treatment Arm - Ivermectin Only Group | 0 |
| Treatment Arm - Fluvoxamine Only Group | 0 |
| Treatment Arm - Metformin and Fluvoxamine Group | 0 |
| Treatment Arm - Metformin and Ivermectin Group | 1 |
(NCT04510194)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Arm - Metformin Only Group | 27 |
| Treatment Arm - Placebo Group | 48 |
| Treatment Arm - Ivermectin Only Group | 16 |
| Treatment Arm - Fluvoxamine Only Group | 15 |
| Treatment Arm - Metformin and Fluvoxamine Group | 18 |
| Treatment Arm - Metformin and Ivermectin Group | 23 |
(NCT04510194)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Arm - Metformin Only Group | 8 |
| Treatment Arm - Placebo Group | 18 |
| Treatment Arm - Ivermectin Only Group | 5 |
| Treatment Arm - Fluvoxamine Only Group | 5 |
| Treatment Arm - Metformin and Fluvoxamine Group | 6 |
| Treatment Arm - Metformin and Ivermectin Group | 4 |
(NCT04510194)
Timeframe: 14 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Treatment Arm - Metformin Only Group | 147 |
| Treatment Arm - Placebo Group | 158 |
| Treatment Arm - Ivermectin Only Group | 88 |
| Treatment Arm - Fluvoxamine Only Group | 73 |
| Treatment Arm - Metformin and Fluvoxamine Group | 71 |
| Treatment Arm - Metformin and Ivermectin Group | 96 |
(NCT04338009)
Timeframe: Up to 28 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Discontinuation Arm | 10 |
| Continuation Arm | 11 |
"The Area Under the Curve of the modified SOFA (AUC SOFA) from daily measurements, weighted to account for the shorter observation period among patients who die in-hospital.~How to interpret the AUC SOFA?: a higher area indicates more severe disease and/or longer hospitalization.The range is 0.1 to 377.3." (NCT04338009)
Timeframe: Up to 28 days
| Intervention | units on a scale (SOFA x days) (Median) |
|---|---|
| Discontinuation Arm | 7 |
| Continuation Arm | 12 |
"The primary endpoint of the trial will be a global rank based on patient outcomes according to four factors: (1) time to death, (2) the number of days supported by invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO), (3) the number of days supported by renal replacement therapy or pressor/inotropic therapy, and (4) a modified sequential Organ Failure Assessment (SOFA) score. The modified SOFA score will include the cardiac, respiratory, renal and coagulation domains of the SOFA score.~How to interpret the rank?: patients are ranked from worst to best outcomes, such that patients with bad outcomes are ranked at the top and patients who have the best outcomes are ranked at the bottom." (NCT04338009)
Timeframe: Up to 28 days
| Intervention | score on a scale (range 1 to 152) (Median) |
|---|---|
| Discontinuation Arm | 81 |
| Continuation Arm | 73 |
Hypotension Requiring Vasopressors, inotropes or mechanical hemodynamic support (ventricular assist device or intra-aortic balloon pump). (NCT04338009)
Timeframe: Up to 28 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Discontinuation Arm | 8 |
| Continuation Arm | 9 |
Need to be transferred to an intensive care unit or to supported by a breathing machine (NCT04338009)
Timeframe: Up to 28 days
| Intervention | Participants (Count of Participants) |
|---|---|
| Discontinuation Arm | 14 |
| Continuation Arm | 16 |
This outcome measurement looked at the median length of hospitalization. (NCT04338009)
Timeframe: Up to 28 days
| Intervention | days (Median) |
|---|---|
| Discontinuation Arm | 5 |
| Continuation Arm | 6 |
(NCT04338009)
Timeframe: Up to 28 days
| Intervention | days (Median) |
|---|---|
| Discontinuation Arm | 15 |
| Continuation Arm | 13 |
Number of patients who were recruited in community healthcare settings who were subsequently admitted to hospital due to COVID-19. (NCT04455815)
Timeframe: Days 1 - 28
| Intervention | Participants (Count of Participants) |
|---|---|
| Camostat | 2 |
| Control Arm | 3 |
Number of days from Day 1 that each patient did not supplementary oxygen (median and range). (NCT04455815)
Timeframe: Days 1 - 28
| Intervention | Days (Median) |
|---|---|
| Camostat | 28 |
| Control Arm | 28 |
Number of days from Day 1 that each patient did not require ventilation (median and range). (NCT04455815)
Timeframe: Days 1 - 28
| Intervention | Days (Median) |
|---|---|
| Camostat | 28 |
| Control Arm | 28 |
Median time and range to worst point on the scale or deterioration of two points or more (from randomisation) on 9 point category ordinal scale. The scale was described in the protocol as follows: '0 - Uninfected, no clinical or virological evidence of infection, 1 - Ambulatory, no limitation of activities, 2 - Ambulatory, limitation of activities, 3 - Hospitalised - mild disease, no oxygen therapy, 4 - Hospitalised - mild disease, oxygen by mask or nasal prongs, 5 - Hospitalised - severe disease, non-invasive, ventilation or high-flow oxygen, 6 - Hospitalised - severe disease, intubation and mechanical ventilation, 7 - Hospitalised - severe disease, ventilation and additional organ support - vasopressors, renal replacement therapy (RRT), extracorporeal membrane oxygenation (ECMO), 8 - Death' (NCT04455815)
Timeframe: Days 1 - 28
| Intervention | Days (Median) |
|---|---|
| Camostat | 0 |
| Control Arm | 0 |
Number of AEs by Severity Grade (mild, moderate, severe) (NCT04455815)
Timeframe: Days 1 - 28
| Intervention | Adverse Events (Number) | |||||
|---|---|---|---|---|---|---|
| Total Mild AEs | Total Moderate AEs | Total Severe AEs | Total Mild AEs related to Camostat | Total Moderate AEs related to Camostat | Total Severe AEs related to Camostat | |
| Camostat | 25 | 10 | 2 | 5 | 6 | 0 |
| Control Arm | 25 | 5 | 2 | NA | NA | NA |
Number of AEs and SAEs assessed as related to camostat by the Investigator. (NCT04455815)
Timeframe: Days 1 - 28
| Intervention | Adverse Events (Number) | |
|---|---|---|
| Total AEs related to Camostat | Total SAEs related to Camostat | |
| Camostat | 11 | 0 |
6 reviews available for camostat and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
Topics: Antiviral Agents; China; Coronavirus Protease Inhibitors; COVID-19; COVID-19 Drug Treatment; Drugs, | 2020 |
The recent outbreaks of human coronaviruses: A medicinal chemistry perspective.
Topics: Antiviral Agents; Chemistry, Pharmaceutical; COVID-19; Disease Outbreaks; Drug Repositioning; Humans | 2021 |
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; Esters; Female; Gabexate; Gene Expression Regulat | 2020 |
Potential therapeutic targets and promising drugs for combating SARS-CoV-2.
Topics: Adenosine Monophosphate; Alanine; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting En | 2020 |
Comprehensive analysis of drugs to treat SARS‑CoV‑2 infection: Mechanistic insights into current COVID‑19 therapies (Review).
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme 2; Betacoronavirus; Bromhexin | 2020 |
Current pharmacological modalities for management of novel coronavirus disease 2019 (COVID-19) and the rationale for their utilization: A review.
Topics: Adenosine Monophosphate; Alanine; Angiotensin-Converting Enzyme 2; Antibodies, Monoclonal, Humanized | 2020 |
2 trials available for camostat and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
One Week of Oral Camostat Versus Placebo in Nonhospitalized Adults With Mild-to-Moderate Coronavirus Disease 2019: A Randomized Controlled Phase 2 Trial.
Topics: Adult; COVID-19; Humans; RNA, Viral; SARS-CoV-2; Time Factors; Treatment Outcome | 2023 |
SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion.
Topics: Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; COVID-19; Esters; Guanidine | 2021 |
27 other studies available for camostat and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
Topics: Animals; Antiviral Agents; Betacoronavirus; Chlorocebus aethiops; Cloning, Molecular; Coronavirus In | 2020 |
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
Topics: Animals; Antiviral Agents; Betacoronavirus; Chlorocebus aethiops; Cloning, Molecular; Coronavirus In | 2020 |
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
Topics: Animals; Antiviral Agents; Betacoronavirus; Chlorocebus aethiops; Cloning, Molecular; Coronavirus In | 2020 |
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing.
Topics: Animals; Antiviral Agents; Betacoronavirus; Chlorocebus aethiops; Cloning, Molecular; Coronavirus In | 2020 |
Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.
Topics: Animals; Anti-Inflammatory Agents; Antiviral Agents; Betacoronavirus; Cell Line; Chlorocebus aethiop | 2020 |
A TMPRSS2 inhibitor acts as a pan-SARS-CoV-2 prophylactic and therapeutic.
Topics: Animals; COVID-19; Disease Models, Animal; Humans; Mice; Mice, Transgenic; SARS-CoV-2; Serine Endope | 2022 |
A novel class of TMPRSS2 inhibitors potently block SARS-CoV-2 and MERS-CoV viral entry and protect human epithelial lung cells.
Topics: Animals; Benzamidines; Benzothiazoles; Cell Line; COVID-19; COVID-19 Drug Treatment; Drug Design; Ep | 2021 |
SARS-CoV-2 Omicron variant shows less efficient replication and fusion activity when compared with Delta variant in TMPRSS2-expressed cells.
Topics: Animals; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Chlorocebus aethiops; Chloroquine; COVID- | 2022 |
Topical TMPRSS2 inhibition prevents SARS-CoV-2 infection in differentiated human airway cultures.
Topics: Administration, Topical; Androgens; Angiotensin-Converting Enzyme 2; Antiviral Agents; Cells, Cultur | 2022 |
Hundreds of COVID trials could provide a deluge of new drugs.
Topics: Adenosine Monophosphate; Administration, Oral; Alanine; Animals; Anti-Inflammatory Agents; Antibodie | 2022 |
Protease inhibitor Camostat Mesyalte blocks wild type SARS-CoV-2 and D614G viral entry in human engineered miniature lungs.
Topics: Animals; Antiviral Agents; COVID-19; Esters; Guanidines; Humans; Lung; Protease Inhibitors; Rats; SA | 2022 |
Inhibition of Listeria Monocytogenes HtrA Protease with Camostat, Gabexate and Nafamostat Mesylates and the Binding Mode of the Inhibitors.
Topics: COVID-19; Gabexate; Humans; Listeria monocytogenes; Mesylates; Peptide Hydrolases; Protease Inhibito | 2023 |
A quantum chemical study on the anti-SARS-CoV-2 activity of TMPRSS2 inhibitors.
Topics: COVID-19; Guanidines; Humans; SARS-CoV-2; Serine Endopeptidases | 2023 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor.
Topics: Ammonium Chloride; Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, V | 2020 |
Learning from our immunological history: What can SARS-CoV teach us about SARS-CoV-2?
Topics: Angiotensin-Converting Enzyme 2; Animals; Antibodies, Neutralizing; Antibodies, Viral; Betacoronavir | 2020 |
Camostat mesilate therapy for COVID-19.
Topics: Animals; Coronavirus Infections; COVID-19; Disease Models, Animal; Esters; Gabexate; Guanidines; Jap | 2020 |
Virtual Screening of Natural Products against Type II Transmembrane Serine Protease (TMPRSS2), the Priming Agent of Coronavirus 2 (SARS-CoV-2).
Topics: Amino Acid Sequence; Betacoronavirus; Catalytic Domain; Computer Simulation; Coronavirus Infections; | 2020 |
Protease Inhibitors: Candidate Drugs to Inhibit Severe Acute Respiratory Syndrome Coronavirus 2 Replication.
Topics: Antiviral Agents; Benzamidines; Betacoronavirus; Cells, Cultured; Coronavirus 229E, Human; Coronavir | 2020 |
The Anticoagulant Nafamostat Potently Inhibits SARS-CoV-2 S Protein-Mediated Fusion in a Cell Fusion Assay System and Viral Infection In Vitro in a Cell-Type-Dependent Manner.
Topics: Angiotensin-Converting Enzyme 2; Angiotensin-Converting Enzyme Inhibitors; Animals; Anticoagulants; | 2020 |
The pivotal role of TMPRSS2 in coronavirus disease 2019 and prostate cancer.
Topics: Androgens; Angiotensin-Converting Enzyme 2; Betacoronavirus; Carcinogenesis; Coronavirus Infections; | 2020 |
Molecular Insights into Human Transmembrane Protease Serine-2 (TMPS2) Inhibitors against SARS-CoV2: Homology Modelling, Molecular Dynamics, and Docking Studies.
Topics: Antiviral Agents; Benzamidines; Betacoronavirus; Coronavirus Infections; COVID-19; Esters; Gabexate; | 2020 |
Rationale for Effective Prophylaxis Against COVID-19 Through Simultaneous Blockade of Both Endosomal and Non-Endosomal SARS-CoV-2 Entry into Host Cell.
Topics: Cathepsin L; COVID-19; Endosomes; Esters; Guanidines; Humans; SARS-CoV-2; Serine Endopeptidases; Vir | 2021 |
Strong Binding of Leupeptin with TMPRSS2 Protease May Be an Alternative to Camostat and Nafamostat for SARS-CoV-2 Repurposed Drug: Evaluation from Molecular Docking and Molecular Dynamics Simulations.
Topics: Antiviral Agents; Benzamidines; COVID-19; COVID-19 Drug Treatment; Drug Repositioning; Esters; Guani | 2021 |
A SARS-CoV-2 cytopathicity dataset generated by high-content screening of a large drug repurposing collection.
Topics: Antiviral Agents; Benzamidines; Caco-2 Cells; Cetylpyridinium; COVID-19; Drug Evaluation, Preclinica | 2021 |
Camostat mesylate therapy in critically ill patients with COVID-19 pneumonia.
Topics: COVID-19; Critical Illness; Esters; Guanidines; Humans; Mesylates; SARS-CoV-2 | 2021 |
Structural Basis of Covalent Inhibitory Mechanism of TMPRSS2-Related Serine Proteases by Camostat.
Topics: Antiviral Agents; Carcinoma, Squamous Cell; COVID-19; COVID-19 Drug Treatment; Esters; Guanidines; H | 2021 |
Identification of 13 Guanidinobenzoyl- or Aminidinobenzoyl-Containing Drugs to Potentially Inhibit TMPRSS2 for COVID-19 Treatment.
Topics: Antiviral Agents; Benzamidines; Binding Sites; Catalytic Domain; COVID-19; COVID-19 Drug Treatment; | 2021 |
Determination of camostat and its metabolites in human plasma - Preservation of samples and quantification by a validated UHPLC-MS/MS method.
Topics: Blood Specimen Collection; Chromatography, High Pressure Liquid; COVID-19; COVID-19 Drug Treatment; | 2021 |
SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination.
Topics: Angiotensin-Converting Enzyme 2; Antibodies, Monoclonal, Humanized; Antibodies, Viral; Cell Line; CO | 2021 |
In silico study on spice-derived antiviral phytochemicals against SARS-CoV-2 TMPRSS2 target.
Topics: Antiviral Agents; COVID-19; Humans; Molecular Docking Simulation; Phytochemicals; SARS-CoV-2; Serine | 2022 |